Summary of the samples and techniques used
| Sample type . | Targeted resequencing of TET2 and DNMT3A . | Sanger sequencing of IDH2* . | GEP . | RRBS . |
|---|---|---|---|---|
| Tumor specimens | ||||
| AITL | 39 | 58 | 36 | 18 |
| PTCL-NOS | 41 | 17 | NA | NA |
| ALK(−) ALCL | 12 | NA | NA | NA |
| Primary CD4+T cells | NA | NA | 5† | 4‡ |
| Tonsils | NA | NA | NA | 3 |
| Sample type . | Targeted resequencing of TET2 and DNMT3A . | Sanger sequencing of IDH2* . | GEP . | RRBS . |
|---|---|---|---|---|
| Tumor specimens | ||||
| AITL | 39 | 58 | 36 | 18 |
| PTCL-NOS | 41 | 17 | NA | NA |
| ALK(−) ALCL | 12 | NA | NA | NA |
| Primary CD4+T cells | NA | NA | 5† | 4‡ |
| Tonsils | NA | NA | NA | 3 |
NA, not applicable.
Low tumor content cases were confirmed by pyrosequencing; 39 of 58 AITL cases have corresponding targeted resequencing data.
Treated with IL-12 for 0, 2, 8, 24, or 48 hours.
Two sets were freshly isolated from donor PBMCs, and the other 2 were cultured with anti-CD3/CD28 beads for 2 weeks before DNA extraction.